



Myriad Genetics Corporate Presentation

05/11/2016





Forward Looking Statements

Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management's current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company's annual reports on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company's projections or forward-looking statements.



Our vision...

A trusted advisor transforming
patients' lives worldwide
with pioneering molecular
diagnostics



The Global Leader in
Personalized Medicine





Myriad's **4ⁱⁿ6** Mission Statement

Answering patients' **four**
most pressing questions

Will I get a disease?

Do I have a disease?

Should I treat this disease?

How should I treat this disease?

In **six** medical
specialties

Oncology

Preventive Care

Urology

Dermatology

Autoimmune

Neuroscience



Unmatched Competitive Advantages in Personalized Medicine




- Profitable R&D driven molecular diagnostic company
- Expertise in DNA, RNA, and proteins
- Strong research capabilities; extensive collaborations (>50 institutions and >20 pharma/bio companies)
- Broad regulatory experience (CLIA, FDA, CE mark)
- Deep physician relationships (>90,000 ordering physicians since inception)
- Extensive managed care contracts (>600)
- Reputation for best-in-class quality for high-complexity tests (>2 million performed)



Our Strategic Goals By 2020



Our Strategic Imperatives to Achieve Our **FIVE**-Year Goals



Transition & Expand the Hereditary Cancer Market




Diversify the Portfolio



Increase International Contribution

Our Strategic Imperatives to Achieve Our **FIVE**-Year Goals



Transition & Expand the Hereditary Cancer Market




Diversify the Portfolio



Increase International Contribution



Hereditary Cancer Revenue Has Been More Durable Than Investors Anticipated






Sustainable Competitive Advantages Expand in the Future



Factor	Lab Accuracy	Variant Classification	Customer Support
Myriad Advantages	<ul style="list-style-type: none">• Requires perfection• 85,000 bases analyzed• 856 distinct manufacturing steps• 23 major technology platforms• 100 proprietary software applications	<ul style="list-style-type: none">• 20 years of research and >\$100M investment• 2 million patients tested• 40,000 variant database that is rapidly expanding• Avoid public databases that are fraught with errors• Proprietary methods	<ul style="list-style-type: none">• 11,000 oncologists and breast surgeons• 35,000 OBGYNs• 375 person sales team• 80 person clinical team• Tailored report developed with >40,000 coding hours• Extensive managed care contracts (>600)• Industry leading turnaround time

Our Strategic Imperatives to Achieve Our **FIVE**-Year Goals



Transition & Expand the Hereditary Cancer Market



Diversify the Portfolio



Increase International Contribution



Industry Leading Pipeline Facilitates Long-Term Growth

Total Addressable Market (TAM)

\$10B

\$8B

\$10B+

Stage 3 REIMBURSEMENT	Stage 2 VALIDATION	Stage 1 DISCOVERY
<ul style="list-style-type: none"> • myRisk Hereditary Cancer • Vectra DA[®] • Prolaris[®] • EndoPredict[®] • BRACAnalysis CDx^{TM1} • Tumor BRACAnalysis CDx[®] 	<ul style="list-style-type: none"> • myPath[®] Melanoma • myChoiceTM HRD (Platinum)² • myChoice HRDTM (PARP)³ • myPlan[®] Lung Cancer • myPlan[®] Renal Cancer 	<ul style="list-style-type: none"> • myPath[®] Bipolar • myPath[®] Pancreatic Cancer • myPath[®] Psoriatic Arthritis • myPath[®] Prostate Cancer • myPath[®] Endometriosis


¹ Ovarian Cancer, Breast Cancer, Pancreatic Cancer

² Triple Negative Breast Cancer, HER2- Breast Cancer

³ Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Metastatic Prostate Cancer


Vectra DA Fills a Substantial Unmet Clinical Need in Rheumatology Market

- Historical methodology for assessing rheumatoid arthritis disease activity has been subjective physician joint assessment (DAS 28)
- Unable to detect changes in disease activity before irreversible bone damage
- Vectra DA is a 12 protein biomarker test that provides an objective assessment of disease activity
- Multiple studies show the tests ability to predict radiographic progression (gold standard endpoint for RA)
- Current volume run rate 170k tests per year
- 1.5 million patients in U.S. with RA
- \$3B global market opportunity



Prolaris Fills Significant Unmet Need in Urology Market

- Helps prostate cancer patients choose between therapy and active surveillance
- 10 clinical studies with >4,000 patients
- Indicated for 500,000 global patients per year with a TAM of \$1.5B
- Medicare reimbursement currently supports \$200M U.S. market
- Signed private contracts representing 28M covered lives
- ≈30% of urologists have ordered the test



*Cuzick 2015 AUA



Complete Suite of Companion Diagnostic Solutions



	BRACAnalysisCDx	TUMOR BRACAnalysisCDx	MYRIAD myChoice [®] HRD	Tumor Panel	Immune Pathway
Sample	Blood	Tumor	Tumor	Tumor	Tumor
Biomarkers	BRCA1&2	Tumor BRCA1&2	Genome-wide assessment of DNA scar associated with DNA repair defects	80+ clinically actionable oncology genes identified by pharma partners	Pathway test to identify responders to immunotherapy
Intellectual Property	Database, process, bioinformatics	Database, process, bioinformatics	MYGN has IP on three proprietary technologies (LOH, TAI, LST)	Database, process, bioinformatics	Patent filed
Currently Marketed	FDA approved	CE Marked	Early access launch for platinum	In research use with major pharma partners	Pursuing pharma collaborations




myPath Melanoma Beginning Reimbursement Process




- 5 clinical studies with \approx 2,000 patients
- Indicated for 400,000 global patients per year with a TAM of \$600M
- 24% of dermatopathologists in the U.S. have ordered the test
- 138% volume growth in FY15

myPath Melanoma Diagnostic Accuracy



Our Strategic Imperatives to Achieve Our **FIVE**-Year Goals



Transition & Expand the Hereditary Cancer Market



Diversify the Portfolio




Increase International Contribution




Refined Strategy to Reflect Unique International Market



COUNTRIES		REFERENCE TESTS		KITS	
Near-Term Growth:	EU6 + Canada	DNA (multiple platforms):		RNA (platform partner):	<ul style="list-style-type: none">• EndoPredict• Prolaris• myPlan Lung• myPath Melanoma• myPlan Renal
Long-Term Growth:	Japan, China, and Brazil			Protein (platform partner):	<ul style="list-style-type: none">• Vectra DA• myPath Bipolar• myPath Pancreatic



Goal to Get to 10% of Revenue From International Markets by FY20






Financial Outlook




Five Year Plan Anticipates Greater Than 10% Revenue CAGR Over Next Five Years





Increased Profitability In Pipeline Products Supports >30% Operating Margins





Capital Deployment Strategy

CAPITAL ALLOCATION PRIORITY	CAPITAL DEPLOYMENT SINCE JUNE 2010	GOAL
R&D	9% of revenue	8% to 10% of revenue
M&A	≈ \$340M	<ul style="list-style-type: none"> • Use cash on hand to fund smaller deals (< \$100M) • Use cash and leverage to fund larger deals (\$100M-\$600M) • Use equity to fund strategic deals (beyond borrowing capacity)
Share Repurchase	>\$1B	<ul style="list-style-type: none"> • Target 100% of FCF • Reduce share repurchases based upon M&A visibility • Maintain cash at \$100M to \$200M
Dividend	None	No plans for dividend given more attractive uses of capital



Worldwide Leader in Personalized Medicine

- We are entering the **golden age** for personalized medicine
- We are the pioneers of “research-based” and “education-centric” business modeling for diagnostics
- No company is better positioned to lead this revolution in healthcare than Myriad

